Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study DOI Open Access
Yoshiki Shimizu,

Shieri Shimodan,

Mariko Hayashida

et al.

Nutrients, Journal Year: 2025, Volume and Issue: 17(4), P. 667 - 667

Published: Feb. 13, 2025

To assess the effects of agrimol-containing Agrimonia pilosa Ledeb. extract (APE) for senescent immune cell removal in middle-aged Japanese adults with immunosenescence. A randomized, double-blind, placebo-controlled, parallel-group study was conducted Japan between June 2023 and April 2024. 110 individuals aged 40-59, selected based on CD8+ T cells highly-expressing-senescence-associated-β-galactosidase (SA-βGal). Participants were randomly assigned to receive 50 mg APE containing 0.2 agrimols or a placebo eight consecutive weeks. The primary endpoint change proportion high SA-βGal expression at 8 weeks intake from baseline. secondary endpoints included CD4+ expression, subsets, ratio various cells. Of 635 subjects screened, immunosenescence this study. In total, 55 participants group 53 completed intervention. There no statistically significant changes either due intake. male population, reduced by (p = 0.044). Furthermore, naïve increased number effector memory decreased consumption APE. suggested reduce cells, indicating its potential as candidate senolytic agent humans; however, results are preliminary data, further research is needed (clinical trial registration: UMIN000051574).

Language: Английский

Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study DOI Open Access
Yoshiki Shimizu,

Shieri Shimodan,

Mariko Hayashida

et al.

Nutrients, Journal Year: 2025, Volume and Issue: 17(4), P. 667 - 667

Published: Feb. 13, 2025

To assess the effects of agrimol-containing Agrimonia pilosa Ledeb. extract (APE) for senescent immune cell removal in middle-aged Japanese adults with immunosenescence. A randomized, double-blind, placebo-controlled, parallel-group study was conducted Japan between June 2023 and April 2024. 110 individuals aged 40-59, selected based on CD8+ T cells highly-expressing-senescence-associated-β-galactosidase (SA-βGal). Participants were randomly assigned to receive 50 mg APE containing 0.2 agrimols or a placebo eight consecutive weeks. The primary endpoint change proportion high SA-βGal expression at 8 weeks intake from baseline. secondary endpoints included CD4+ expression, subsets, ratio various cells. Of 635 subjects screened, immunosenescence this study. In total, 55 participants group 53 completed intervention. There no statistically significant changes either due intake. male population, reduced by (p = 0.044). Furthermore, naïve increased number effector memory decreased consumption APE. suggested reduce cells, indicating its potential as candidate senolytic agent humans; however, results are preliminary data, further research is needed (clinical trial registration: UMIN000051574).

Language: Английский

Citations

0